Intestinal Mesenchymal Stem Stells and Inflammatory Bowel Diseases (COSMIC)
27. december 2021 opdateret af: University Hospital, Montpellier
Characterization of Mesenchymal Stem Cells From the Colon and Small Intestine of Patients With Inflammatory Bowel Disease - The COSMIC Study
The exact origin of inflammatory bowel disease (IBD) is still unknown.
The current hypothesis is that IBD is secondary to an abnormal intestinal immun response directed to all or part of the intestinal flora in genetically predisposed individuals.
Several experimental studies have demonstrated the ability of mesenchymal stem cells (MSCs) from bone marrow or adipose tissue origin to control intestinal inflammation in animal models.
However, to date, there are no data regarding the functions of resident MSCs in the colon and small intestine of IBD patients.
We hypothesize that dysfunction of resident intestinal MSCs contributes to the disruption of intestinal homeostasis in patients with IBD causing the development of intestinal inflammation.
The aim of this research project is to identify, describe and characterize at the molecular and functional level MSCs of the colon and small intestine of patients with Crohn's disease and ulcerative colitis and to compare them with a control population.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Primary and secondary objectives:
Main Objective: Characterize morphologically, molecularly and functionally the MSCs of colon and small intestine of patients with IBD and compared to MSCs of colon and small intestine of control patients.
Secondary objectives: To study the reaction of colon and small intestine MHC in patients with IBD following stimulation with bacterial compounds.
Methodology:
Clinical study exploratory translational physiopathological. Two groups of patients with Crohn's disease and ulcerative colitis who require colonoscopy or surgery for intestinal resection will be included. These two groups will be compared to a control group consisting of patients requiring colonoscopy for screening or intestinal resection for colorectal cancer or diverticulum.
Intestinal sampling by biopsy during the colonoscopy or with surgical specimen during the surgery will be performed to isolate the MSCs.
The outcome measures will be a qualitative and quantitative analysis of MSCs by immunohistochemistry, immunofluorescence, cell proliferation and differentiation, production of pro- and anti-inflammatory cytokines in the basal state and after bacterial stimulation.
Total of 60 patients (20 in groups, 15 with colonoscopy and 5 with surgical specimens).
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
2
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Montpellier, Frankrig, 34080
- Hôpital St Eloi
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 75 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion criteria:
For IBD patients :
- Age between 18 and 75 year old
- Diagnosis of Crohn's disease or ulcertaive colitis according to internationla guidelines
- Endoscopically active disease
- Indication for colonoscopy or intestinal resection according to standard of care
- Written inform consent
For control patients :
- Age between 18 and 75 year old
- Indication for screening colonoscopy for irritable bowel syndrome, diverticulum or colorectal cancer surveillance according to standard of care
- Indication for intestinal resection for diverticulum or colorectal cancer according to standard of care
- Written inform consent
Exclusion criteria:
For IBD patients :
- Active intestinal infection
- Confirmed intestinal parasitosis
- Intestinal stoma
For control patients :
- Active intestinal infection
- Confirmed intestinal parasitosis
- Intestinal inflammation at colonoscopy
- Chronic intestinal inflammation on biopsies
- Absence of healthy tissue on surgical specimen
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: Crohn's disease patient group
Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
|
Intestinal biopsies during colonoscopy
biopsies taken on surgical specimen after intestinal resection
|
|
Andet: Ulcerative colitis patient group
Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
|
Intestinal biopsies during colonoscopy
biopsies taken on surgical specimen after intestinal resection
|
|
Andet: Control group
Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
|
Intestinal biopsies during colonoscopy
biopsies taken on surgical specimen after intestinal resection
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proliferation and differentiation of intestinal MSCs in IBD patients.
Tidsramme: 1 month
|
Proliferation and differentiation of intestinal MSCs in IBD patients.
|
1 month
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Comparison of MSCs between IBD patients and control patients
Tidsramme: 1 month
|
Comparison of MSCs between IBD patients and control patients using mmunohistochemistry, immunofluorescence, quantification of pro- and anti-inflammatory cytokines production.
|
1 month
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Guillaume Pineton de Chambrun, University Hospital, Montpellier
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
21. november 2018
Primær færdiggørelse (Faktiske)
13. februar 2019
Studieafslutning (Faktiske)
13. februar 2019
Datoer for studieregistrering
Først indsendt
10. april 2017
Først indsendt, der opfyldte QC-kriterier
10. april 2017
Først opslået (Faktiske)
14. april 2017
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
28. december 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
27. december 2021
Sidst verificeret
1. december 2021
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 9755 (Anden identifikator: UK Clinical Research Network)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Ingen
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Inflammatoriske tarmsygdomme
-
Chinese PLA General HospitalAfsluttetSepsis | SIRS (Systemic Inflammatory Response Syndrome)Kina
-
Chinese PLA General HospitalUkendtSepsis | SIRS (Systemic Inflammatory Response Syndrome)Kina
-
University of ArkansasAfsluttetPædiatriske patienter med SIRS (Systemic Inflammatory Response Syndrome)Forenede Stater
-
Hacettepe UniversityAfsluttetKolorektal cancer | Ammende | Koloskopi forberedelse | Boston Bowel Preparation ScaleKalkun
-
Seoul National University HospitalUkendtSund og rask | Kronisk forstoppelse | Constipated Irritable Bowel Syndrome
-
Seoul National University Boramae HospitalDong-A ST Co., Ltd.Ikke rekrutterer endnuSlidgigt | Rheumatoid arthritis | Enteritis | Mavesår | Ankyloserende spondylitis | Anden muskuloskeletal lidelse | NSAID-associeret gastropati | NSAID (Non-Steroidal Anti-inflammatory Drug) Induceret Enteropati